Excerpt from: Forbes (click for full article)
In yet another blow to a potential treatment for Alzheimer’s disease, Baxter International BAX +3.57% (BAX) said its late-stage clinical trial failed to meet its endpoints for “reducing cognitive decline and preserving functional abilities” for patients.
Like other treatments once they reach the third phase and a broader clinical trial with more patients, Baxter’s drug did not “indicate a statistically “significant difference in the rate of cognitive decline as compared to placebo.” Here’s a link to Baxter’s statement on the trials end.
Though Baxter’s biologic derived from plasma known as intravenous immuno globulin (IVIG) was seldom mentioned alongside other companies working on Alzheimer’s treatments like Pfizer PFE 0% (PFE), Merck (MRK), Johnson and Johnson (JNJ) and Eli Lilly (LLY), it was unique in that the product was already on the market. Gammagard is used primarily as an immune system booster and could have reached Alzheimer’s patients sooner given doctors could technically have prescribed it earlier.
But hopes for Alzheimer’s patients with moderate and mild disease are the latest to be dashed.
Comments